Sacubitril/valsartan

Drug Profile

Sacubitril/valsartan

Alternative Names: AHU-377/valsartan; Entresto; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Rovi
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure
  • Phase III Essential hypertension; Hypertension; Kidney disorders

Most Recent Events

  • 26 Aug 2017 Updated efficacy data from the phase III PARADIGM-HF trial in Heart failure presented at the Annual Congress of the European Society of Cardiology (ESC-2017)
  • 14 Aug 2017 Novartis initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (EudraCT2017-001803-57)
  • 16 Jul 2017 Efficacy and adverse events data from a phase II trial in Hypertension presented at the 27th European Meeting on Hypertension and Cardiovascular Protection (ESH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top